{"id":"NCT02345226","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","officialTitle":"A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-26","primaryCompletion":"2016-06-29","completion":"2019-01-02","firstPosted":"2015-01-26","resultsPosted":"2017-10-19","lastUpdate":"2020-01-02"},"enrollment":881,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"FTC/RPV/TAF","otherNames":["Odefsey®"]},{"type":"DRUG","name":"EFV/FTC/TDF Placebo","otherNames":[]},{"type":"DRUG","name":"EFV/FTC/TDF","otherNames":["Atripla®"]},{"type":"DRUG","name":"FTC/RPV/TAF Placebo","otherNames":[]}],"arms":[{"label":"FTC/RPV/TAF","type":"EXPERIMENTAL"},{"label":"EFV/FTC/TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open Label Extension Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen of efavirenz /FTC/tenofovir disoproxil fumarate (EFV/FTC/TDF) FDC in virologically-suppressed HIV-1 infected participants.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"FTC/RPV/TAF","deltaMin":90,"sd":null},{"arm":"EFV/FTC/TDF","deltaMin":92,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.35"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":11},"locations":{"siteCount":117,"countries":["United States","Belgium","Canada","France","Germany","Puerto Rico","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["30101539","28259776"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":438},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Cough","Arthralgia"]}}